CA3010862A1 - Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques - Google Patents
Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques Download PDFInfo
- Publication number
- CA3010862A1 CA3010862A1 CA3010862A CA3010862A CA3010862A1 CA 3010862 A1 CA3010862 A1 CA 3010862A1 CA 3010862 A CA3010862 A CA 3010862A CA 3010862 A CA3010862 A CA 3010862A CA 3010862 A1 CA3010862 A1 CA 3010862A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- vegf
- drug
- aflibercept
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
La présente invention concerne des méthodes et des dispositifs pour le traitement de la dégénérescence maculaire liée à l'âge (DMLA) humide, la néovascularisation choroïdienne (CNV), la DMLA humide associée à la CNV et/ou la DMLA humide associée à l'occlusion veineuse rétinienne (RVO) chez un sujet humain qui en a besoin. Selon certains aspects, les dispositifs décrits dans la présente description comprennent un récipient de médicament délimitant une lumière conçue pour contenir un médicament, une partie terminale distale du récipient de médicament comprenant une partie d'accouplement conçue pour être accouplée amovible à un ensemble aiguille, une partie terminale proximale du récipient de médicament comprenant un rebord et un épaulement longitudinal ; un ensemble piston comprenant une partie terminale distale disposée mobile à l'intérieur de la lumière du récipient de médicament ; et une poignée accouplée à une partie terminale proximale de l'ensemble piston.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662276543P | 2016-01-08 | 2016-01-08 | |
US62/276,543 | 2016-01-08 | ||
US201662324708P | 2016-04-19 | 2016-04-19 | |
US62/324,708 | 2016-04-19 | ||
PCT/US2017/012757 WO2017120601A1 (fr) | 2016-01-08 | 2017-01-09 | Méthodes et dispositifs pour le traitement de troubles oculaires postérieurs avec l'aflibercept et d'autres substances biologiques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3010862A1 true CA3010862A1 (fr) | 2017-07-13 |
Family
ID=59274052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3010862A Abandoned CA3010862A1 (fr) | 2016-01-08 | 2017-01-09 | Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3400014A1 (fr) |
JP (1) | JP2019501200A (fr) |
KR (1) | KR20180101488A (fr) |
CN (1) | CN108778330A (fr) |
AU (1) | AU2017206114A1 (fr) |
BR (1) | BR112018013805A2 (fr) |
CA (1) | CA3010862A1 (fr) |
MX (1) | MX2018008469A (fr) |
WO (1) | WO2017120601A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
JP5996544B2 (ja) | 2010-10-15 | 2016-09-21 | クリアサイド・バイオメディカル・インコーポレーテッドClearside Biomedical Incorporated | 眼球アクセス用装置 |
SG11201503637SA (en) | 2012-11-08 | 2015-06-29 | Clearside Biomedical Inc | Methods and devices for the treatment of ocular diseases in human subjects |
CN105246529B (zh) | 2013-05-03 | 2019-06-14 | 科尼尔赛德生物医学公司 | 用于眼部注射的设备和方法 |
EP3003454B1 (fr) | 2013-06-03 | 2020-01-08 | Clearside Biomedical, Inc. | Appareil pour une administration de médicament à l'aide de multiples réservoirs |
MX370207B (es) | 2013-07-23 | 2019-12-05 | Novaliq Gmbh | Composiciones estabilizadas de anticuerpos. |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
AU2017248731A1 (en) | 2016-04-15 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
WO2017192565A1 (fr) | 2016-05-02 | 2017-11-09 | Clearside Biomedical, Inc. | Systèmes et méthodes pour l'administration de médicaments par voie ophtalmique |
CA3072847A1 (fr) | 2016-08-12 | 2018-02-15 | Clearside Biomedical, Inc. | Dispositifs et procedes de reglage de la profondeur d'insertion d'une aiguille pour administration de medicament |
WO2019067540A1 (fr) * | 2017-09-27 | 2019-04-04 | Regenxbio Inc. | Traitement de maladies oculaires avec un fab anti-vegf à modification post-traductionnelle totalement humain |
JP2021506885A (ja) * | 2017-12-20 | 2021-02-22 | エンジェクス ファーマシューティカル インコーポレイテッド | マルチキナーゼ阻害剤としてのカルバメートおよび尿素化合物 |
CN108030783A (zh) * | 2017-12-27 | 2018-05-15 | 广东众生药业股份有限公司 | 乐伐替尼在制备防治黄斑变性的药物中的用途 |
KR20210021299A (ko) | 2018-05-10 | 2021-02-25 | 리제너론 파아마슈티컬스, 인크. | 고농도 vegf 수용체 융합 단백질 함유 제제 |
CN110693886B (zh) * | 2018-07-09 | 2022-12-06 | 天津医科大学 | 防治脑海绵状血管畸形病变的药物 |
KR20200101160A (ko) * | 2019-02-19 | 2020-08-27 | 전남대학교산학협력단 | 리보세라닙을 포함하는 안구 신생혈관 억제용 약학 조성물 및 이를 이용한 안구 신생혈관 억제 방법 |
US20220143221A1 (en) * | 2019-04-03 | 2022-05-12 | Regenxbio, Inc. | Gene Therapy For Eye Pathologies |
CN110522909B (zh) * | 2019-09-30 | 2024-02-20 | 安徽省立医院 | 一种协同增强抗her2阳性肿瘤效果的药物组合 |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
MX2022005034A (es) * | 2019-11-11 | 2022-05-16 | Cstone Pharmaceuticals Suzhou Co Ltd | Combinacion farmaceutica y uso de la misma. |
WO2021168218A1 (fr) * | 2020-02-19 | 2021-08-26 | Clearside Biomedical, Inc. | Compositions comprenant de l'axitinib et méthodes de traitement de troubles oculaires |
WO2021257193A1 (fr) * | 2020-06-15 | 2021-12-23 | Opko Pharmaceuticals, Llc | Formulations ophtalmiques topiques à base de liposomes chargés d'acétonide de triamcinolone en tant que thérapie primaire pour un œdème maculaire secondaire à une occlusion de la veine rétinienne ramifiée |
BR112023023002A2 (pt) * | 2021-05-17 | 2024-01-23 | Bayer Healthcare Llc | Regimes estendidos de antagonistas de vegf em altas doses para tratamento de doenças oculares angiogênicas |
CN113546176B (zh) * | 2021-06-30 | 2024-03-15 | 南通大学 | 一种特异性用于抑制眼内血管新生药物合成方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG194471A1 (en) * | 2011-05-27 | 2013-12-30 | Novartis Ag | Method of treating vision disorders |
CA2865132A1 (fr) * | 2012-02-22 | 2013-08-29 | Trustees Of Tufts College | Compositions et procedes pour administration oculaire d'un agent therapeutique |
SG11201503637SA (en) * | 2012-11-08 | 2015-06-29 | Clearside Biomedical Inc | Methods and devices for the treatment of ocular diseases in human subjects |
CA2933900A1 (fr) * | 2013-12-20 | 2015-06-25 | Georgia Tech Research Corporation | Preparations et procedes servant a introduire de maniere ciblee des agents therapeutiques dans l'il |
RU2017101236A (ru) * | 2014-06-17 | 2018-07-17 | Клиасайд Байомедикал, Инк. | Способы и устройства для лечения патологических нарушений в заднем сегменте глаза |
-
2017
- 2017-01-09 CN CN201780015406.9A patent/CN108778330A/zh active Pending
- 2017-01-09 BR BR112018013805-3A patent/BR112018013805A2/pt not_active Application Discontinuation
- 2017-01-09 EP EP17736528.5A patent/EP3400014A1/fr not_active Withdrawn
- 2017-01-09 KR KR1020187022893A patent/KR20180101488A/ko unknown
- 2017-01-09 JP JP2018535400A patent/JP2019501200A/ja active Pending
- 2017-01-09 MX MX2018008469A patent/MX2018008469A/es unknown
- 2017-01-09 AU AU2017206114A patent/AU2017206114A1/en not_active Abandoned
- 2017-01-09 CA CA3010862A patent/CA3010862A1/fr not_active Abandoned
- 2017-01-09 WO PCT/US2017/012757 patent/WO2017120601A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2017120601A1 (fr) | 2017-07-13 |
CN108778330A (zh) | 2018-11-09 |
EP3400014A1 (fr) | 2018-11-14 |
JP2019501200A (ja) | 2019-01-17 |
KR20180101488A (ko) | 2018-09-12 |
MX2018008469A (es) | 2018-11-09 |
AU2017206114A1 (en) | 2018-08-02 |
BR112018013805A2 (pt) | 2018-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210260047A1 (en) | Methods and devices for the treatment of ocular diseases in human subjects | |
KR102511477B1 (ko) | 안구 후부 질환을 치료하기 위한 방법 및 디바이스 | |
CA3010862A1 (fr) | Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques | |
US20220280341A1 (en) | Apparatus and methods for drug delivery using microneedles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20210831 |
|
FZDE | Discontinued |
Effective date: 20210831 |